[1] Martin-Pelaez S, Fito M, Castaner O. Mediterranean diet effects on type 2 diabetes prevention, disease progression, and related mechanisms. A review. Nutrients, 2020, 12(8):39-42. [2] Tinajero M G, Malik V S. An update on the epidemiology of type 2 diabetes: a global perspective. Endocrinol Metab Clin North Am, 2021, 50(3):337-355. [3] Tanase D M, Gosav E M, Costea C F, et al. The intricate relationship between type 2 diabetes mellitus, insulin resistance, and nonalcoholic fatty liver disease. J Diabetes Res, 2020, 48(15):196-198. [4] Targher G, Corey K E, Byrne C D, et al. The complex link between NAFLD and type 2 diabetes mellitus-mechanisms and treatments. Nat Rev Gastroenterol Hepatol, 2021, 18(9):599-612. [5] 莫超艳, 杨有强, 钟嫄, 等. 非酒精性脂肪性肝病合并2型糖尿病患者血清抵抗素和黄醇结合蛋白4水平及其临床意义探讨.实用肝脏病杂志, 2022, 25(2):231-234. [6] Deb A, Deshmukh B, Ramteke P, et al. Resistin: a journey from metabolism to cancer. Transl Oncol, 2021, 14(10):178-182. [7] 王新军, 于文. 2012年糖尿病诊疗指南——美国糖尿病协会. 国际内分泌代谢杂志, 2012, 32(3):211-214. [8] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版). 实用肝脏病杂志, 2018, 21(2):177-186. [9] Sun W, Cui H, Li N, et al. Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: a meta-analysis study. Hepatol Res, 2016, 46(9):862-870. [10] Caussy C, Aubin A, Loomba R. The relationship between type 2 diabetes, NAFLD, and cardiovascular risk. Curr Diab Rep, 2021, 21(5):15-19. [11] 李江佩, 孙音, 孔祥波, 等. 2型糖尿病合并非酒精性脂肪性肝病患者血清细胞角蛋白-18片段M30、脂联素和视黄醇结合蛋白4水平的变化及临床意义.临床和实验医学杂志, 2022, 21(9):941-945. [12] Cernea S, Raz I. NAFLD in type 2 diabetes mellitus: Still many challenging questions. Diabetes Metab Res Rev, 2021, 37(2):386-392. [13] Padda J, Khalid K, Khedr A, et al. Non-alcoholic fatty liver disease and its association with diabetes mellitus. Cureus, 2021, 13(8):321-326. [14] Kim H, Lee D S, An T H, et al. Metabolic spectrum of liver failure in type 2 diabetes and obesity: from nafld to nash to HCC. Int J Mol Sci, 2021, 22(9):45-49. [15] Marusic M, Paic M, Knobloch M, et al. NAFLD, insulin resistance, and diabetes mellitus type 2. Can J Gastroenterol Hepatol, 2021, 21(8):827-832. [16] 李翔, 牟涛, 李益飞, 等. 阻塞性睡眠呼吸暂停与缺血性卒中患者甘油三酯葡萄糖指数的相关性.国际脑血管病杂志, 2022, 30(3):184-189. [17] Recinella L, Orlando G, Ferrante C, et al. Adipokines: new potential therapeutic target for obesity and metabolic, rheumatic, and cardiovascular diseases. Front Physiol, 2020, 11(14):966-968. [18] Tao L C, Xu J N, Wang T T, et al. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol, 2022, 21(1):68-72. [19] Farkhondeh T, Llorens S, Pourbagher-Shahri A M, et al. An overview of the role of adipokines in cardiometabolic diseases. Molecules, 2020, 25(21):48-53. [20] Li Y, Yang Q, Cai D, et al. Resistin, a novel host defense peptide of innate immunity. Front Immunol, 2021, 12(8):807-812. [21] Ramdas N V, Satheesh P, Shenoy M T, et al. Triglyceride glucose index: a surrogate biomarker of insulin resistance. J Pak Med Assoc, 2022, 72(5):986-988. |